Who Is Patient Val Ashton With Premature Baby Luna on Greys Anatomy? – 2paragraphs Buzz

Mackenzie Marsh on Grey's Anatomy (ABC)

In the Greys Anatomy episode Fight the Power, while Bailey (Chandra Wilson) panics as she hears there has been a surge of COVID-19 cases, and Jackson (Jesse Williams) and Richard (James Pickens Jr.) team up against Catherine (Debbie Allen) to teach her a lesson, Carina (Stefania Spampinato) checks in with her patient Val Ashton (Mackenzie Marsh).

In the previous episode My Happy Ending a recently divorced Val came to the hospital with abdominal pain no knowing that she was pregnant. It turned out that a fetus was growing near her liver. After Carina performed an emergency C-section, Val named her 26-week-old daughter Luna who was intubated and then taken to the NICU.

Actress Mackenzie Marsh is known for her roles on Charmed (Knansie), Will & Grace (Vinces cousin and Drews ex-wife Angela), The Following (Tilda), and the 2016 movie Pee-wees Big Holiday (Judy Brown), among others.

Greys Anatomy airs Thursdays at 9 pm on ABC, right after Station 19 at 8 pm.

Read more here:
Who Is Patient Val Ashton With Premature Baby Luna on Greys Anatomy? - 2paragraphs Buzz

Is neuroscience the key to protecting AI from adversarial attacks? – TechTalks

This article is part of ourreviews of AI research papers, a series of posts that explore the latest findings in artificial intelligence.

Deep learning has come a long way since the days it could only recognize hand-written characters on checks and envelopes. Today, deep neural networks have become a key component of many computer vision applications, from photo and video editors to medical software and self-driving cars.

Roughly fashioned after the structure of the brain, neural networks have come closer to seeing the world as we humans do. But they still have a long way to go and make mistakes in situations that humans would never err.

These situations, generally known as adversarial examples, change the behavior of an AI model in befuddling ways. Adversarial machine learning is one of the greatest challenges of current artificial intelligence systems. They can lead machine learning models failing in unpredictable ways or becoming vulnerable to cyberattacks.

Creating AI systems that are resilient against adversarial attacks has become an active area of research and a hot topic of discussion at AI conferences. In computer vision, one interesting method to protect deep learning systems against adversarial attacks is to apply findings in neuroscience to close the gap between neural networks and the mammalian vision system.

Using this approach, researchers at MIT and MIT-IBM Watson AI Lab have found that directly mapping the features of the mammalian visual cortex onto deep neural networks creates AI systems that are more predictable in their behavior and more robust to adversarial perturbations. In a paper published on the bioRxiv preprint server, the researchers introduce VOneNet, an architecture that combines current deep learning techniques with neuroscience-inspired neural networks.

The work, done with help from scientists at the University of Munich, Ludwig Maximilian University, and the University of Augsburg, was accepted at the NeurIPS 2020, one of the prominent annual AI conferences, which will be held virtually this year.

The main architecture used in computer vision today is convolutional neural networks (CNN). When stacked on top of each other, multiple convolutional layers can be trained to learn and extract hierarchical features from images. Lower layers find general patterns such as corners and edges, and higher layers gradually become adept at finding more specific things such as objects and people.

In comparison to the traditional fully connected networks, ConvNets have proven to be both more robust and computationally efficient. There remain, however, fundamental differences between the way CNNs and the human visual system process information.

Deep neural networks (and convolutional neural networks in particular) have emerged as surprising good models of the visual cortexsurprisingly, they tend to fit experimental data collected from the brain even better than computational models that were tailor-made for explaining the neuroscience data, David Cox, IBM Director of MIT-IBM Watson AI Lab, told TechTalks. But not every deep neural network matches the brain data equally well, and there are some persistent gaps where the brain and the DNNs differ.

The most prominent of these gaps are adversarial examples, in which subtle perturbations such as a small patch or a layer of imperceptible noise can cause neural networks to misclassify their inputs. These changes go mostly unnoticed to the human eye.

It is certainly the case that the images that fool DNNs would never fool our own visual systems, Cox says. Its also the case that DNNs are surprisingly brittle against natural degradations (e.g., adding noise) to images, so robustness in general seems to be an open problem for DNNs. With this in mind, we felt this was a good place to look for differences between brains and DNNs that might be helpful.

Cox has been exploring the intersection of neuroscience and artificial intelligence since the early 2000s, when he was a student of James DiCarlo, neuroscience professor at MIT. The two have continued to work together since.

The brain is an incredibly powerful and effective information processing machine, and its tantalizing to ask if we can learn new tricks from it that can be used for practical purposes. At the same time, we can use what we know about artificial systems to provide guiding theories and hypotheses that can suggest experiments to help us understand the brain, Cox says.

For the new research, Cox and DiCarlo joined Joel Dapello and Tiago Marques, the lead authors of the paper, to see if neural networks became more robust to adversarial attacks when their activations were similar to brain activity. The AI researchers tested several popular CNN architectures trained on the ImageNet data set, including AlexNet, VGG, and different variations of ResNet. They also included some deep learning models that had undergone adversarial training, a process in which a neural network is trained on adversarial examples to avoid misclassifying them.

The scientist evaluated the AI models using the BrainScore metric, which compares activations in deep neural networks and neural responses in the brain. They then measured the robustness of each model by testing it against white-box adversarial attacks, where an attacker has full knowledge of the structure and parameters of the target neural networks.

To our surprise, the more brain-like a model was, the more robust the system was against adversarial attacks, Cox says. Inspired by this, we asked if it was possible to improve robustness (including adversarial robustness) by adding a more faithful simulation of the early visual cortexbased on neuroscience experimentsto the input stage of the network.

To further validate their findings, the researchers developed VOneNet, a hybrid deep learning architecture that combines standard CNNs with a layer of neuroscience-inspired neural networks.

The VOneNet replaces the first few layers of the CNN with the VOneBlock, a neural network architecture fashioned after the primary visual cortex of primates, also known as the V1 area. This means that image data is first processed by the VOneBlock before being passed on to the rest of the network.

The VOneBlock is itself composed of a Gabor filter bank (GFB), simple and complex cell nonlinearities, and neuronal stochasticity. The GFB is similar to the convolutional layers found in other neural networks. But while classic neural networks with random parameter values and tune them during training, the values of the GFB parameters are determined and fixed based on what we know about activations in the primary visual cortex.

The weights of the GFB and other architectural choices of the VOneBlock are engineered according to biology. This means that all the choices we made for the VOneBlock were constrained by neurophysiology. In other words, we designed the VOneBlock to mimic as much as possible the primate primary visual cortex (area V1). We considered available data collected over the last four decades from several studies to determine the VOneBlock parameters, says Tiago Marques, PhD, PhRMA Foundation Postdoctoral Fellow at MIT and co-author of the paper.

While there are significant differences in the visual cortex of different primate, there are also many shared features, especially in the V1 area. Fortunately, across primates differences seem to be minor and in fact there are plenty of studies showing that monkeys object recognition capabilities resemble those of humans. In our model with used published available data characterizing responses of monkeys V1 neurons. While our model is still only an approximation of primate V1 (it does not include all known data and even that data is somewhat limited there is a lot that we still do not know about V1 processing), it is a good approximation, Marques says.

Beyond the GFB layer, the simple and complex cells in the VOneBlock give the neural network flexibility to detect features under different conditions. Ultimately, the goal of object recognition is to identify the existence of objects independently of their exact shape, size, location and other low-level features, Marques says. In the VOneBlock it seems that both simple and complex cells serve complementary roles in supporting performance under different image perturbations. Simple cells were particularly important for dealing with common corruptions while complex cells with white box adversarial attacks.

One of the strengths of the VOneBlock is its compatibility with current CNN architectures. The VOneBlock was designed to have a plug-and-play functionality, Marques says. That means that it directly replaces the input layer of a standard CNN structure. A transition layer that follows the core of the VOneBlock ensures that its output can be made compatible with rest of the CNN architecture.

The researchers plugged the VOneBlock into several CNN architectures that perform well on the ImageNet data set. Interestingly, the addition of this simple block resulted in considerable improvement in robustness to white-box adversarial attacks and outperformed training-based defense methods.

Simulating the image processing of primate primary visual cortex at the front of standard CNN architectures significantly improves their robustness to image perturbations, even bringing them to outperform state-of-the-art defense methods, the researchers write in their paper.

The model of V1 that we added here is actually quite simplewere only altering the first stage of the system, while leaving the rest of the network untouched, and the biological fidelity of this V1 model is still quite simple, Cox says, adding that there is a lot more detail and nuance one could add to such a model to make it better match what is known about the brain.

Simplicity is strength in some ways, since it isolates a smaller set of principles that might be important, but it would be interesting to explore whether other dimensions of biological fidelity might be important, he says.

The paper challenges a trend that has become all too common in AI research in the past years. Instead of applying the latest findings about brain mechanisms in their research, many AI scientists focus on driving advances in the field by taking advantage the availability of vast compute resources and large data sets to train larger and larger neural networks. And as weve discussed in these pages before, that approach presents many challenges to AI research.

VOneNet proves that biological intelligence still has a lot of untapped potential and can address some of the fundamental problems AI research is facing. The models presented here, drawn directly from primate neurobiology, indeed require less training to achieve more human-like behavior. This is one turn of a new virtuous circle, wherein neuroscience and artificial intelligence each feed into and reinforce the understanding and ability of the other, the authors write.

In the future, the researchers will further explore the properties of VOneNet and the further integration of discoveries in neuroscience and artificial intelligence. One limitation of our current work is that while we have shown that adding a V1 block leads to improvements, we dont have a great handle onwhyit does, Cox says.

Developing the theory to help understand this why question will enable the AI researchers to ultimately home in on what really matters and to build more effective systems. They also plan to explore the integration of neuroscience-inspired architectures beyond the initial layers of artificial neural networks.

Says Cox, Weve only just scratched the surface in terms of incorporating these elements of biological realism into DNNs, and theres a lot more we can still do. Were excited to see where this journey takes us.

Here is the original post:
Is neuroscience the key to protecting AI from adversarial attacks? - TechTalks

Innovative Companies Diving into The Neuro Market Ahead of 2021 – BioSpace

With the expected Emergency Use Authorization (EUA) of Pfizer-BioNTech and Modernas COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience?

It will if the following five companies, which all launched this year with Series A financing, have anything to say about it.

Vigil Neuroscience

Led by industry veteran Ivana Magovevi-Liebisch, Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia.

A type of neuroglia located throughout the brain and spinal cord, microglia are the first line of immune defense for the central nervous system (CNS). As they are responsible for detecting plaques, damaged or unnecessary neurons, synapses, and infections, their inefficiency can lead to neuroinflammatory, neuropsychiatric, and neurodegenerative diseases, including Epilepsy, Parkinsons disease Multiple Sclerosis, and many types of dementia.

Vigils pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction.

Vigils $50 million Series A financing, completed this week, was powered by Atlas Ventures and Northpond Ventures, and includes participating investors Hatteras Partners and Alexandria Venture Investments. Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., which will remain a key shareholder.

SciNeuro Pharmaceuticals

SciNeuro Pharmaceuticals was also born this week, launched by Lilly Asia Ventures Fund and Arch Venture Partners, co-leaders of its $100 million Series A financing.

The financing advances the establishment of a robust and innovative CNS pipeline, focusing initially on the Greater China region.

One in every six people in China is living with a CNS condition, yet there are relatively few effective treatments available today, underscoring the urgent need to develop and deliver novel, effective therapies. The impact of CNS diseases extends beyond patients to their families and society as well, said SciNeuro Founder and chief executive officer, Min Li, Ph.D., in a statement.

Li is a prominent neuroscientist and former professor at Johns Hopkins Medicine. His company, which also includes Qiuqing Ang, M.D., Ph.D. as chief medical officer, and Danny Chen, Ph.D. as SVP & Head of Translational Science, will be particularly focused on CNS diseases where there is a major unmet need.

Genesis Therapeutics

Spun out of CEO and co-founder Evan Feinbergs breakthrough artificial Intelligence (AI) research at Stanford Universitys Pande Lab, Genesis Therapeutics is applying the resulting influential PotentialNet neural network algorithm to unify AI and biotech against a range of diseases with unmet needs.

Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets, Feinberg said at the time of the launch.

Genesis went public on December 2 in a round of $52 million Series A financing led by Rock Springs Capital. Dr. Kris Jenner of Rock Springs, who joins Genesis board of directors, is a renowned healthcare investor who has invested in several successful biotech companies.

Libra Therapeutics

California-based Libra Therapeutics launched in September with $29 million in Series A financing, co-led by Boehringer Ingelheim Venture Fund (BIVF), Epidarex Capital and Sant.

Libra, which means balance when translated to English, hopes to restore balance to the brains neurons. The company plans to do this by developing drugs that eliminate protein aggregation by either reducing the production of toxic proteins or removing them after the fact through autophagy.

Its like taking out the trash. It clears out the toxic proteins that build up in the neuron, thereby allowing the neuron to function properly, said Libra President and CEO Isaac Veinbergs, formerly of Acadia Pharmaceuticals and Sanofi.

Libra will use this approach, along with the $29 million infusion, to develop novel small molecule drug candidates for the treatment of neurodegenerative diseases.

Tranquis Therapeutics

An immuno-neurology company with a focus on neurodegenerative and aging-related diseases,Tranquis Therapeutics beat the aforementioned four to the show, launching on July 9 with $30 million in Series A funding, led by Remiges Ventures and SR One.

Tranquis platform is based on the groundbreaking work of its scientific founder, Professor Edgar Engleman, M.D., and his team at Stanford University, which posits that myeloid immune cell dysfunction underlies a variety of nervous system disorders.

The company is developing small molecule therapeutic candidates that cross the blood-brain barrier to target the underlying myeloid immune cell dysfunction associated with many CNS diseases.

While its original work focused on orphan diseases such as Frontotemporal Dementia and Amyotrophic Lateral Sclerosis, the team, led by President and CEO Sanjay Kakkar, M.D., will branch out to join the fight against more widespread illnesses, Parkinsons and Alzheimers.

For our lead program, TQS-168, we have demonstrated in vitro the ability to restore a key metabolic pathway we have shown is dysfunctional in the myeloid immune cells of patients with neurodegenerative diseases, as well as highly encouraging in vivo effects in challenging neurodegenerative disease models, Kakkar said at the time of the launch.

Most read today on BioSpace:

More here:
Innovative Companies Diving into The Neuro Market Ahead of 2021 - BioSpace

Timeline of key events in McMaster’s investigation in its Department of Psychology, Neuroscience and Behaviour – TheSpec.com

Investigation into McMaster's psychology department and sexual violence on campus

For nearly a year, McMaster has been investigating serious allegations of sexual assault and sexual harassment involving individuals in its Department of Psychology, Neuroscience and Behaviour (PNB).

On Thursday, the university released a report on the findings of a review into the department. The report found there are systemic and cultural issues within the PNB, including numerous reports of sexual harassment, and a degree of complacency that has let inappropriate behaviours go unchecked.

But while the report into the culture of the department is now complete, investigations into the more serious allegations of sexual harassment and sexual violence remain ongoing.

Below is a timeline of the events in 2020 that unfolded leading up to this weeks report.

Feb. 19: Maureen J. MacDonald, dean of science, sends an email to the PNB department and students affected by the situation stating a professor in the department has been suspended and barred from campus following serious allegations that possibly involve a number of university policies, including the sexual violence policy.

March 19: The Spectator obtains a copy of MacDonalds letter and confirms police are investigating Scott Watter, a professor in McMasters PNB department. Watters lawyer confirms his client has been placed on nondisciplinary leave of absence without loss of pay pending the outcome of an investigation into alleged breaches of university policies.

June 18: Police put out a release saying Watter, 46, is facing charges of sexual assault and sexual assault causing bodily harm for incidents that occurred in 2017 involving a female student. Police say they believe there may be other victims.

July 27: McMaster retains Rubin Thomlinson LLP, a law firm specializing in workplace investigations, to conduct a systemic review of the Department of Psychology, Neuroscience and Behaviour.

July 28: McMaster announces its original investigation under the universitys sexual violence and discrimination and harassment policies is being broadened to identify any potential systemic or cultural issues within the department that need to be surfaced and addressed. The broadened investigation is the climate review.

The university also announces it has suspended two more department faculty members. The faculty members are also banned from campus. They are not named, nor is anyone else sanctioned by the university in coming months. The university also does not provide details regarding the allegations levelled against the faculty members, nor does it provide details of allegations against those sanctioned.

Aug. 6: McMaster says a graduate student has been suspended and is no longer allowed on campus. The decision came after new allegations came to light relating to the universitys sexual violence and discrimination and harassment policies.

Aug. 21: McMaster says it has restricted another faculty member from interacting with students after new allegations were made under the universitys discrimination and harassment policy.

Sept. 30: McMaster says a former staff member in the PNB department who now works in another area of the university is on a leave of absence after a complaint about an alleged past sexual assault. The person is also banned from campus. Additionally, a second person who is a current department staff member was barred from interacting with students due to a separate allegation. The university said it was investigating both incidents under the universitys sexual violence policy.

Dec. 3: The university announces the review is complete and releases a report on its findings. The review uncovered systemic and cultural issues, including allegations of sexual harassment and a lack of boundaries between students and faculty, and a degree of complacency that has let inappropriate behaviours go unchecked, the report states.

Loading...Loading...Loading...Loading...Loading...

On Dec. 24: Watter is next scheduled to appear in court.

Moving forward: The university says that it will implement such measures as additional trauma-informed training for department staff and faculty. For students, it will offer training on sexual harassment, including providing information on accessing support. Equity, diversity and inclusion expertise will be provided to the department. The university will also commit to helping the department build on its research and teaching strengths.

Here is the original post:
Timeline of key events in McMaster's investigation in its Department of Psychology, Neuroscience and Behaviour - TheSpec.com

Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors – GlobeNewswire

CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced today that it has added Ruth McKernan, Ph.D., CBE, FMedSci, to serve as an independent member of its Board of Directors. Dr. McKernan currently serves as a venture partner with SV Health Investors, LLP, a global investment firm and specialist healthcare fund manager, where she supports companies that create new medicines for treating neurodegenerative disorders. With over 25 years of academic, research and commercial experience in the pharmaceutical industry, Dr. McKernan also serves as chairperson of the BioIndustry Association, a trade association for innovative life sciences in the United Kingdom, and as a trustee of Alzheimers Research UK, the countrys leading dementia research charity.

Dr. McKernan is an outstanding scientific leader with deep expertise in the biopharmaceutical industry and she will bring a wealth of knowledge and experience in neuroscience disorders to our board, said Tony Coles, M.D., chief executive officer and chairperson of Cerevel Therapeutics. Dr. McKernans guidance will help us as we seek to innovate the treatment landscape and bring new therapies to individuals facing some of the most vexing diseases including schizophrenia, epilepsy and Parkinsons disease.

I am honored to join the board of Cerevel, a neuroscience company that is working hard to bring new treatments to patients, said Dr. McKernan. Cerevel aspires to be the premier neuroscience company, and I look forward to contributing to the realization of that goal.

About Dr. Ruth McKernanDr. McKernans distinguished career has spanned the academic, business and government worlds. She has over 25 years of research and commercial experience in the pharmaceutical industry, including leading research units in the United Kingdom and the United States. Currently, Dr. McKernan is a venture partner with SV Health Investors, LLP, a global investment firm focused on the healthcare industry. At SV, Dr. McKernan focuses on companies that create new medicines for treating neurodegenerative disorders, including AstronauTx, a UKbased biotechnology company for which she serves as chairperson. She also serves as chairperson of the BioIndustry Association, a trade association for innovative life sciences in the United Kingdom, and as a trustee of Alzheimers Research UK.

Previously, Dr. McKernan served in a variety of senior leadership roles while at Pfizer, including as vice president, chief scientific officer of Regenerative Medicine, and chief scientific officer of Neusentis. In those roles, she initiated multiple neuroscience partnerships, acquisitions and spinouts and played an active part in taking more than 10 compounds into the clinic. Prior to Pfizer, Dr. McKernan served in multiple senior positions at Merck over the course of an 18-year tenure at the company. As a neuroscientist, Dr. McKernan has over 120 publications and 15 patents in the areas of ion channels and regenerative medicine. Her first book for nonscientists, Billys Halo, was shortlisted for the Mind Book of the Year Award (2007), a literary award which celebrates writing that contributes to public understanding of mental health issues. Dr. McKernan earned her bachelors degree in pharmacology with biochemistry from Kings College London and received a Ph.D. in biochemical pharmacology from the University of London.

About Cerevel TherapeuticsCerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company seeks to unlock the science surrounding new treatment opportunities through understanding the neurocircuitry of neuroscience diseases and associated symptoms. Cerevel Therapeutics has a diversified pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinsons, epilepsy, schizophrenia and substance use disorders. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit http://www.cerevel.com.

Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about our potential to become a premier neuroscience company. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:Rachel EidesW2O purereides@purecommunications.com

Investor Contact:Matthew CalistriCerevel Therapeuticsmatthew.calistri@cerevel.com

Read more:
Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors - GlobeNewswire

Aural Analytics, Inc. Announces the Launch of a Large-Scale Pivotal Study for Its Respiratory and Speech Motor Control Prediction Software Tools -…

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Aural Analytics, Inc., the industry leader in speech neuroscience and speech analytics technologies, announced today the initiation of a multi-product pivotal study to demonstrate the safety and efficacy of its speech-based tools for measuring pulmonary function and speech motor function in amyotrophic lateral sclerosis (ALS). The company anticipates submitting the results of this multi-site, multi-language, 280 participant, prospective, blinded study to the U.S. Food and Drug Administration (FDA) in late 2021. The study, conducted as part of the Target ALS Diagnosis Initiative, is one of several pivotal studies Aural Analytics is set to kick off in 2021 as it expands its suite of clinical-grade speech-based digital tools.

The Aural Analytics VCP software tool enables on-demand, real-time objective evaluation of pulmonary function by predicting forced vital capacity (FVC) and forced expiratory volume (FEV1) without the need for specialized hardware in-clinic and at-home. These measurements are commonly used in the assessment of airflow obstruction (COPD, asthma) and restrictive lung disease (ALS). The VCP software is currently being used as one approach to screen for eligibility in the Healey Center ALS platform trial at Massachusetts General Hospital. Aural Analytics will also use the study to further demonstrate the safety and efficacy of its speech-based assessment software that enables on-demand, real-time objective monitoring of symptoms and progression in diseases known to impact bulbar function (speech and swallowing).

Aural Analytics is enabling clinical-grade speech analytics in areas of critical unmet patient and clinical need. This study will be the basis of multiple regulatory submissions for products that have broad clinical utility and commercial pathways, said Daniel Jones, co-founder and CEO of Aural Analytics. We continue to work closely with regulators at the FDA and key stakeholders across the healthcare industry to ensure safe, reliable, repeatable and transparent speech-based tools are brought to market.

More about the Aural Analytics VCP Software in ALS

Respiratory failure is the leading cause of death in patients with ALS. As a result, regular assessment of respiratory function is the standard of care. People with ALS often have problems achieving valid measures on standard in-clinic or at-home spirometers. Lip weakness can prevent creation of a tight seal around the spirometer and some with ALS experience an involuntary slamming shut of their vocal cords when they exhale forcefully. Spirometers often induce bouts of coughing which, given the COVID-19 pandemic, has made it increasingly difficult to objectively measure respiratory function in-clinic. Our VCP software is designed to tap into both inspiratory and expiratory muscle strength, without requiring lip strength, and with far less chance of inducing laryngospasm or coughing, said Dr. Julie Liss, co-founder and chief clinical officer at Aural Analytics. Our application enables a patient to easily deliver pulmonary function data, remotely, with just a few short tasks. The outcome measures are clinically relevant, interpretable, reliable and highly repeatable.

More about the Aural Analytics Speech Motor Control Software

Functional rating scales have been used historically to capture the impact of disease on a person's daily life. These rating scales are often coarse, subjective, and can miss key information about how a patient is doing. We have found that the information we extract from speech samples tracks well with a number of functional rating scales for different diseases, said Dr. Liss. Yet, more importantly, our speech metrics can detect changes in disease before they have functional consequences and in a far more frequent, objective way. We believe this tool will provide an opportunity for greater precision in clinical management.

The Aural Analytics VCP and speech motor assessment applications further add to the companys technology suite which includes mobile applications currently available for use in clinical research and clinical settings, an embeddable mobile and web SDK, web-progressive applications, and APIs, all with cloud-based computation that power disease-specific speech tasks and analytics.

About Aural Analytics, Inc.

Aural Analytics is the industrys leading speech neuroscience company building the worlds most advanced clinical-grade speech analytics platform for health applications across the lifespan. Its suite of mobile-first, patient-centric applications, available in up to 30 languages across Android, iOS and the web are easy to use, secure, and provide robust, clinically relevant, interpretable and validated metrics reflecting the neurological and respiratory health of its users. The company is founded on nearly three decades of NIH and NSF-funded research in speech neuroscience, is backed by dozens of high-caliber scientific publications, and has won several awards for its work in the field, including the prestigious Global SCRIP Award for Best Technology Development in Clinical Trials. Aural Analytics is based in Scottsdale, AZ. For more information, please visit auralanalytics.com or follow Aural Analytics on Twitter, LinkedIn, Medium and Facebook.

About Target ALS

Target ALS is a 501(c)(3) medical research foundation committed to the search for effective treatments for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrigs disease. We envision a world in which no one dies of ALS and play a unique role in the battle against this disease. Founded in 2013 by former New York City deputy mayor Dan Doctoroff who lost both his father and uncle to ALS our approach is breaking down barriers and silos that previously inhibited research results. We do this through our Target ALS Innovation Ecosystem, which facilitates unparalleled collaboration between researchers from academia and the pharma/biotech industry. The Target ALS Innovation Ecosystem has revolutionized the field in just seven years through collaborations that have resulted in the first potential treatments since ALS was identified in 1869.

To date, the Target ALS Innovation Ecosystem, which launched in 2013 and set the groundwork for the new Target ALS Diagnosis Initiative, has yielded 175+ research projects, 12+ therapeutic targets and five clinical trials, to date.

About The Target ALS Diagnosis Initiative

Target ALS launched the first-ever comprehensive effort to discover ALS biomarkers The Target ALS Diagnosis Initiative through which the organization will invest $15 million in collaborative grantmaking and the development of new scientific resources. The initiative was developed in response to input from over 100 scientists, patients, caregivers and other thought leaders. They universally identified ALS biomarkers as a critical unmet need to diagnose the disease early, track its progression and provide reliable measures for new treatments.

The Target ALS Diagnosis Initiative strategically focuses on three promising areas:

See the article here:
Aural Analytics, Inc. Announces the Launch of a Large-Scale Pivotal Study for Its Respiratory and Speech Motor Control Prediction Software Tools -...

Global Neuroscience Antibodies and Assays Market Analysis by 2020-2025 – Industry Today

The global Neuroscience Antibodies and Assaysmarket size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

Read the original here:
Global Neuroscience Antibodies and Assays Market Analysis by 2020-2025 - Industry Today

Neuroscientists Use Pac-Man Style Video Games To Study The Origin Of Human Emotions – Hot Hardware

While anyone could say a good movie, book, or video game made them feel emotional, scientists did not understand why until now. A research team at the University of Geneva, Switzerland, found that emotions result from the synchronization of several neural systems throughout the brain. They found this out by analyzing volunteers' "feelings, expressions, and physiological responses" while playing a video game designed for arousing different emotions depending on the game's progress.As the University of Geneva press release explains, "Emotions are complex phenomena that influence our minds, bodies, and behavior." This complexity makes emotions challenging to understand and study. Previously, theories "have attempted to model the emergence of an emotion, although none has so far been proven experimentally." Moreover, experiments relating to emotions were more "targeted," such as showing a volunteer an image or video to try and extract emotion from a specific area of the brain. "The problem is, these [neural] regions overlap for different emotions, so they're not specific," as one area of the brain, says Joana Leito, a post-doctoral neuroscience fellow at the university. On the other hand, video games can evoke emotions and target different areas of the brain at one time, making them a viable candidate for experimentation with volunteers.With the thought of video games in mind, the neuroscientists at the University of Geneva created a video game to evoke emotions by putting volunteers "in situations they'll have to evaluate so they can advance and win rewards," as Dr. Leito explains. The game is similar to Pac-Man in a way, where players need to grab coins, interact with "nice monsters," ignore the "neutral monsters," and avoid the "bad guys" to win points and go to the next level. These game features create scenarios that trigger different emotions through a theoretical model called the component process model, whereby other neurological pieces come together to form an emotional state. During the game, the researchers were then able to study volunteers' brain activity through facial imaging, feelings through questions, and physiology through several other methods. Once the study was complete, the researchers could conclusively state that emotions are created when different brain components work in parallel to create an emotional state. This finding "validat[es] the idea that emotion is grounded in action-oriented functions in order to allow an adapted response to events." While there could be more happening inside the brain when emotions are created, we now have a base understanding of the 'why' emotions happen, and thanks to video games, no less. My mom always said video games were bad for my brain, but maybe they were just making me more emotionally developed.

View post:
Neuroscientists Use Pac-Man Style Video Games To Study The Origin Of Human Emotions - Hot Hardware

Why did the Human Brain Project Crash and Burn? – Walter Bradley Center for Natural and Artificial Intelligence

The Human Brain Project from 2013 sounded like science fiction in an EU setting: We will build a brain in a decade: And, if we do succeed, we will send, in ten years, a hologram to talk to you.

Well, we all got one thing right. It was fiction. Filmmaker Noah Hutton, a sympathetic observer, chronicled the decline, producing a documentary, In Silico, that focuses on booster Henry Markram who, according to his TED talk bio from 2009, was director of Blue Brain, a supercomputing project that can model components of the mammalian brain to precise cellular detail and simulate their activity in 3D. Soon hell simulate a whole rat brain in real time.

When the project started to wobble, many neuroscientists were angry and disappointed:

But that year (2010), Hutton also started to encounter critics in the neuroscience community. They claimed that the simulation project was premature because too little was known about the different types of neuron in the brain and how they were wired. Anyone can repair a broken watch by putting its known components in the right places, neuroscientist Zachary Mainen at the Champalimaud Centre for the Unknown in Lisbon, Portugal, tells the camera. Try this with the incompletely understood components of the brain, he says, and youll end up with a bunch of parts that doesnt tell the time.

By 2014, about 750 neuroscientists had signed a letter pledging that they wouldnt participate and by 2016, Markram was no longer in charge.

And the whole brain maps? They never happened.

Reflecting on the premiere of the documentary, science writer Alison Abbott tells us,

Hutton hints that the disputes were driven by money. I disagree; my sense is that it came down to leadership style and irresolvable differences in scientific opinion. There is a bolder, even more interesting, story waiting to be told.

Abbott does not spell out the irresolvable differences in scientific opinion but we cant help wondering if they relate to the question of whether the brain can be understood in such a simplistic way.

Some thoughts from The Guardian in 2014:

Central to the latest controversy are recent changes made by Henry Markram, head of the Human Brain Project at the Swiss Federal Institute for Technology in Lausanne. The changes sidelined cognitive scientists who study high-level brain functions, such as thought and behaviour. Without them, the brain simulation will be built from the bottom up, drawing on more fundamental science, such as studies of individual neurons. The brain, the most complex object known, has some 86bn neurons and 100tn connections.

The main apparent goal of building the capacity to construct a larger-scale simulation of the human brain is radically premature, Peter Dayan, director of the computational neuroscience unit at UCL, told the Guardian.

Some thoughts from The Scientist in 2015:

After weathering serious criticism last year, the European Commission-backed effort to map the brains neural connections must reform or die, a review panel says.

Its been a rough nine months for the European Commissions Human Brain Project (HBP). More than 250 of Europes top neuroscientists threatened to boycott the $1.6 billion effort to create a computer simulation of the human brain last July, and now a European Commission (EC) review panel has echoed some of the same concerns voiced by those scientists.

Some thoughts from HBC, a portal dedicated to fast computers, in 2019:

From the outset, HBP was beset by criticism unrealistic goals, un-useful goals, poor organization, waste of scarce research resources said many. Others argued its big goals would lead to big insights as well as myriad useful tools. Its hard to gloss over the HBPs problems, but perhaps too easy to understate its contributions Whether the HBP was and is tilting at windmills is a significant question.

Tilting at windmills along with Don Quixote maybe? (See the illustration of the outcome of the Dons famous attempt to charge a windmill.) What if the brain is not only not a computer but not even like a computer?

As neuroscientist Yuri Danilov has pointed out, Right now people are saying, each synoptical connection is a microprocessor. So if its a microprocessor, you have 1012 neurons, each neuron has 105 synapses, so you have you can compute how many parallel processing units you have in the brain if each synapse is a microprocessor. But as soon as you assume that each neuron is a microprocessor, you assume that there is a programmer. There is no programmer in the brain; there are no algorithms in the brain.

The human brain exceeds the most powerful computers in efficiency. Its also not clear exactly how it works. Lemurs, with brains 1/200th the size of a chimpanzees brain, passed the same IQ test. And this is to say nothing of the little understood relationship between the human brain and the human mind.

Underlying the quarrels and stalemates of the Human Brain Project may be practical problems with the idea of simply simulating the brain on a computer.

You may also enjoy:

Do we really have free will? Four things to know

and

Your mind vs. your brain: Ten things to know

Read more:
Why did the Human Brain Project Crash and Burn? - Walter Bradley Center for Natural and Artificial Intelligence

Cerevel Therapeutics to Host Investor Webcast Moderated by Stifel – GlobeNewswire

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced it will host a live webcast providing a current corporate overview, followed by a moderated question and answer session on Monday, December 14.

The live webcast will be from 11:00 a.m. to noon EST with presentations from Tony Coles, M.D., chairperson and chief executive officer, Ray Sanchez, M.D., chief medical officer, and John Renger, Ph.D., chief scientific officer. The question and answer session will also include Kathy Yi, chief financial officer, and will be moderated by Paul Matteis, managing director and senior biotech analyst at Stifel.

The live webcast can be accessed on the investor relations section of the Cerevel Therapeutics website here. A replay will be available in the same section of the companys website for approximately 90 days.

About Cerevel TherapeuticsCerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinsons disease and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit http://www.cerevel.com.

Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential attributes and benefits of our product candidates, the format and timing of our product development activities and clinical trials, including the expected timing of data announcements, and the sufficiency of our financial resources. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: that clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading Risk Factors in our definitive proxy statement/prospectus filed with the SEC on October 7, 2020. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:Rachel EidesW2O purereides@purecommunications.com

Investor Contact:Matthew CalistriCerevel Therapeuticsmatthew.calistri@cerevel.com

See more here:
Cerevel Therapeutics to Host Investor Webcast Moderated by Stifel - GlobeNewswire